Sex Hormones and the Liver: Implications for Disease Progression and Hormonal Therapy
Liver International · 2026-02 · 46 (2)
DOI: 10.1111/liv.70509 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 06.01.2026. Verfasst von Nora Cazzagon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy. Hauptthemen laut MEDLINE: Gonadal Steroid Hormones, Liver Diseases, Liver, Hormone Replacement Therapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 202 Literaturangaben. Gefördert von: Agenzia Italiana del Farmaco, Ministero della Salute.
Abstract (Originalsprache)
The liver is central to sex hormone metabolism, and sex hormones in turn modulate hepatic physiology and disease processes. Oestrogens are often protective, while androgens tend to worsen disease progression. The clinical implications of hormonal therapies in patients with liver disease remain an area of active investigation. To review current evidence on the interplay between sex hormones and liver disease, with a focus on the safety and impact of hormonal therapies, including contraception, hormone replacement therapy, assisted reproductive technology and gender‐affirming treatments. Prolonged or high‐dose oestrogen exposure, particularly via oral contraceptives, has been associated with intrahepatic cholestasis and hepatocellular adenoma (HCA), especially in predisposed individuals. In contrast, hormone replacement therapy in postmenopausal women is generally safe and may confer metabolic and hepatic benefits. Oestrogens appear to slow fibrosis progression and reduce hepatocellular carcinoma risk, whereas androgens can promote steatosis and HBV‐related oncogenesis. Hormonal therapies are safe in most patients with compensated chronic liver disease but require caution in settings such as in polycystic liver disease, where oestrogens can accelerate cyst growth. Emerging data also indicate a role of sex hormones in autoimmune and cholestatic diseases, as well as in outcomes of assisted reproduction and gender‐affirming therapy. Hormonal therapies are feasible in most liver disease contexts, but individualised assessment, awareness of genetic predisposition, and disease‐specific risks are essential to optimise safety and therapeutic benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
- Gastroenterology Unit, University Hospital of Padova, Padova, Italy.
- Multivisceral Transplant Unit, University Hospital of Padova, Padova, Italy.
- Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
- CHIMOMO Department, University of Modena & Reggio Emilia, Modena, Italy.
- University of Padova, Padova, Italy.
ORCID-Profile: Nora Cazzagon, Maurizia Rossana Brunetto, Erica Villa, Patrizia Burra
Förderung
- Agenzia Italiana del Farmaco, Ministero della Salute
Zitieren
APA
Cazzagon, N., Gambato, M., Brunetto, M. R., Villa, E., Burra, P., Floreani, A., & Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF) (2026). Sex Hormones and the Liver: Implications for Disease Progression and Hormonal Therapy. Liver International, 46(2). https://doi.org/10.1111/liv.70509
Vancouver
Cazzagon N, Gambato M, Brunetto MR, Villa E, Burra P, Floreani A, et al. Sex Hormones and the Liver: Implications for Disease Progression and Hormonal Therapy. Liver International. 2026;46(2). doi:10.1111/liv.70509
BibTeX
@article{Cazzagon2026,
author = {Cazzagon, Nora and Gambato, Martina and Brunetto, Maurizia Rossana and Villa, Erica and Burra, Patrizia and Floreani, Annarosa and Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF), Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF)},
title = {Sex Hormones and the Liver: Implications for Disease Progression and Hormonal Therapy},
journal = {Liver International},
year = {2026},
volume = {46},
number = {2},
doi = {10.1111/liv.70509}
}
EUVIMED